<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00766376</url>
  </required_header>
  <id_info>
    <org_study_id>ERf-02</org_study_id>
    <nct_id>NCT00766376</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Evaluation of Erbium Treatment</brief_title>
  <official_title>Safety and Efficacy Evaluation of Fractional Erbium Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Palomar Medical Technologies, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Palomar Medical Technologies, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this research study is to evaluate the safety and effectiveness of erbium
      lasers for dermatological cosmetic procedures.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this investigation is to evaluate erbium laser devices for dermatological
      cosmetic procedures.

      Each subject will undergo up to 6 treatment sessions, with scheduled time-points for
      follow-up visits. The Investigator determines the number of treatments. Subjects may be
      treated on there face, neck, chest or other body areas as deemed appropriate by the
      Investigator. At each visit, the treated areas will be clinically evaluated for side effects
      and will also have photographs taken of their treated areas. Subjects will be asked to
      complete a self-assessment questionnaire at different time points throughout their study
      participation.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Active, not recruiting</last_known_status>
  <start_date>July 2007</start_date>
  <completion_date type="Anticipated">July 2009</completion_date>
  <primary_completion_date type="Anticipated">July 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants That Scored Above a One Category (Mild) Improvement Using the Fitzpatrick Wrinkle Scale.</measure>
    <time_frame>participants at three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants That Have Reduction in Pigmented Lesions and Dyschromia.</measure>
    <time_frame>participants at three months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">151</enrollment>
  <condition>Skin Aging</condition>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Erbium laser</intervention_name>
    <description>Erbium laser treatment. Each subject will undergo up to 6 treatment sessions</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male and female Adults (18 years or older).

          -  Subjects who can read, understand, and sign the Informed Consent Form.

          -  Subjects willing and able to comply with all study requirements.

        Exclusion Criteria:

          -  Subjects with active localized or systemic infections.

          -  Immunocompromised subjects.

          -  Subjects with coagulation disorder.

          -  History of skin photo sensitivity disorders, or use of photosensitizing drugs (e.g.,
             tetracycline or sulfa drugs).

          -  Pregnant and/or lactating (All female volunteers will be advised about using birth
             control during the period of study).

          -  In the opinion of the trained clinician, subject is unwilling or unable to adhere to
             all study requirements, including application and follow-up visits.

          -  Use of AccutaneÂ® within the past 6 months.

          -  Subjects with a history of radiation therapy to the treatment area.

          -  Subjects with any skin pathology or condition that could interfere with evaluation or
             with the use of typical ancillary medical treatments or care used before, during or
             after treatments.

          -  Subjects have undergone dermatological procedures (e.g., laser or light treatments)
             for the treatment of wrinkles, skin resurfacing, or skin rejuvenation in the treatment
             area within 1 year of study participation.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Scripps Clinic Laser &amp; Cosmetic Dermatology</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Palomar Medical Technologies, Inc.</name>
      <address>
        <city>Burlington</city>
        <state>Massachusetts</state>
        <zip>01803</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brooke Seckel, MD</name>
      <address>
        <city>Concord</city>
        <state>Massachusetts</state>
        <zip>01742</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin &amp; Laser Surgery Center</name>
      <address>
        <city>Nashua</city>
        <state>New Hampshire</state>
        <zip>03060</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas Southwestern Medical Center at Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 30, 2008</study_first_submitted>
  <study_first_submitted_qc>October 1, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 3, 2008</study_first_posted>
  <results_first_submitted>January 6, 2010</results_first_submitted>
  <results_first_submitted_qc>January 6, 2010</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 29, 2010</results_first_posted>
  <last_update_submitted>January 6, 2010</last_update_submitted>
  <last_update_submitted_qc>January 6, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 29, 2010</last_update_posted>
  <responsible_party>
    <name_title>Medical Director</name_title>
    <organization>Palomar Medical Technologies, Inc.</organization>
  </responsible_party>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Erbium Laser</title>
          <description>Each Subject will undergo 1 - 6 treatment sessions, with 5 scheduled time-points for follow-up visits. Additional follow-up visits may be required to accommodate optional biopsies or to evaluate any concerns related to the course of healing. At each visit, the treated areas will be clinically evaluated and photographed.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="151"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="124"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="27"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Erbium Laser</title>
          <description>Each subject will undergo a minimum of 1 treatment with 5 scheduled follow-up visits. Additional follow-up visits may be required to accommodate optional biopsies or to evaluate any concerns related to the course of healing. At each visit, the treated areas will be clinically evaluated and photographed.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="124"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="55" spread="8.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="116"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants That Scored Above a One Category (Mild) Improvement Using the Fitzpatrick Wrinkle Scale.</title>
        <description>To assess wrinkle improvement, 3 blinded evaluators use the validated Fitzpatrick Wrinkle Scale (FWS), a 0 to 9 (0=no wrinkles, 9=severe wrinkles) point scale to score the degree of wrinkles, fine lines, and the severity of skin elastosis. Evaluators assign a FWS score to pre-treatment and post-treatment photographs. The difference between the two scores is the amount (i.e., category) of wrinkle improvement. An improvement of one category means a mild improvement in wrinkle reduction.</description>
        <time_frame>participants at three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erbium Laser</title>
            <description>Each Subject will undergo 1 - 6 treatment sessions, with 5 scheduled time-points for follow-up visits. Additional follow-up visits may be required to accommodate optional biopsies or to evaluate any concerns related to the course of healing. At each visit, the treated areas will be clinically evaluated and photographed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Scored Above a One Category (Mild) Improvement Using the Fitzpatrick Wrinkle Scale.</title>
          <description>To assess wrinkle improvement, 3 blinded evaluators use the validated Fitzpatrick Wrinkle Scale (FWS), a 0 to 9 (0=no wrinkles, 9=severe wrinkles) point scale to score the degree of wrinkles, fine lines, and the severity of skin elastosis. Evaluators assign a FWS score to pre-treatment and post-treatment photographs. The difference between the two scores is the amount (i.e., category) of wrinkle improvement. An improvement of one category means a mild improvement in wrinkle reduction.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants That Have Reduction in Pigmented Lesions and Dyschromia.</title>
        <description>To assess reductions in pigmented lesions and dyschromia, blinded evaluators were asked to assess pre-treatment and post-treatment photographs. The blinded evaluators were asked to grade percent improvement for pigmentation using a 0 to 10 scale (0=none and 10=severe) and the following quartile improvement scale: 1=1-24%, 2=25-49%, 3=50-74% and 4=75-100%. The blinded-evaluator scores were tabulated and analyzed in order to assess the effects.</description>
        <time_frame>participants at three months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Erbium Laser</title>
            <description>Each Subject will undergo 1 - 6 treatment sessions, with 5 scheduled time-points for follow-up visits. Additional follow-up visits may be required to accommodate optional biopsies or to evaluate any concerns related to the course of healing. At each visit, the treated areas will be clinically evaluated and photographed.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants That Have Reduction in Pigmented Lesions and Dyschromia.</title>
          <description>To assess reductions in pigmented lesions and dyschromia, blinded evaluators were asked to assess pre-treatment and post-treatment photographs. The blinded evaluators were asked to grade percent improvement for pigmentation using a 0 to 10 scale (0=none and 10=severe) and the following quartile improvement scale: 1=1-24%, 2=25-49%, 3=50-74% and 4=75-100%. The blinded-evaluator scores were tabulated and analyzed in order to assess the effects.</description>
          <units>Participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="151"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="124"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Minimum of 3 months post treatment, or until adverse events resolve</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Erbium Laser</title>
          <description>Each Subject will undergo 1 - 6 treatment sessions, with 5 scheduled time-points for follow-up visits. Additional follow-up visits may be required to accommodate optional biopsies or to evaluate any concerns related to the course of healing. At each visit, the treated areas will be clinically evaluated and photographed.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Petechiae</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Edema</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="123" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Erythema</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="124" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bleeding</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="98" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Oozing</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="71" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Skin Texture Changes</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Bronzing</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="67" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Sloughing</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Shrinkage</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Increased Sensitivity</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="40" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Crusting</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="55" subjects_at_risk="124"/>
              </event>
              <event>
                <sub_title>Hyperpigmentation</sub_title>
                <description>Transient side effects all resolved.</description>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="124"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Director of Regulatory Affairs</name_or_title>
      <organization>Palomar Medical Technologies, Inc.</organization>
      <phone>781-993-2414</phone>
      <email>stimberlake@palomarmedical.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

